REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Chemistry: Molecular Biology And Microbiology > Micro-organism, Tissue Cell Culture Or Enzyme Using Process To Synthesize A Desired Chemical Compound Or Composition > Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide > Fusion Proteins Or Polypeptides Fusion Proteins Or PolypeptidesFusion Proteins Or Polypeptides patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/15/07 - 20070037258 - Methods and compositions for enhancing protein folding The present invention relates to methods and compositions for enhancing protein folding. In particular, the present invention relates to methods for directing recombinantly expressed proteins to protein folding chaperones. ... 02/08/07 - 20070031938 - Organic anion transporting (oat)-like protein ust3-like1 and uses thereof The present invention is directed to a polynucleotide sequence of a novel organic anion transporting (OAT)-like protein UST3-like1. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary ... 01/18/07 - 20070015258 - Alpha-beta c4bp -type recombinant heteromultimeric proteins A recombinant heteromultimeric protein including at least (a) a polypeptide fusion molecule A consisting of a C4BP α-chain C-terminal fragment and a polypeptide fragment heterologous to said a chain, and (b) a polypeptide fusion molecule B consisting of a C4BP β-chain C-terminal fragment and a polypeptide fragment heterologous to said ... 12/21/06 - 20060286641 - Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof Polypeptides and multimeric polypeptides capable of binding interferon α and/or interferon β which are useful therapeutically in methods of treating interferon α/β-related conditions or diseases. ... 11/23/06 - 20060263856 - Expression technology for proteins containing a hybrid isotype antibody moiety Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may ... 11/23/06 - 20060263855 - Intein-mediated protein purification using in vivo expression of an elastin-like protein Purification of recombinant proteins is performed by expressing in a host cell a fusion protein comprising: (a) a product protein domain, (b) an intein, and (c) at least one aggregator protein domain, wherein the aggregator protein domain comprises a self-aggregating protein such as elastin-like proteins (ELPs). ... 11/16/06 - 20060257974 - Fusion proteins of hiv regulatory/accessory proteins Nucleic acids are disclosed encoding fusion proteins comprising the amino acid sequence of at least four non-attenuated HIV proteins selected from the group consisting of Vif, Vpr, Vpu, Vpx, Rev, Tat, and Nef, wherein the fusion protein does not contain a specific cleavage sequence for a cellular protease. Also disclosed ... 11/09/06 - 20060252130 - Method for linking molecular substances The invention relates to a method for linking two or more molecular substances, by means of adapter segments, which bring about a targeted interaction based upon the affinity of proline-rich amino acid sequences and protein domains of the type WW. ... 09/14/06 - 20060205037 - Modified transferrin fusion proteins Modified fusion proteins of a transferrini moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment ... 09/07/06 - 20060199251 - Cleavage of fusion proteins using granzyme b protease A method for the preparation of a polypeptide of interest in authentic form by enzymatic cleavage of fusion proteins using Granzyme B protease (EC 3.4.21.79). There is also provided fusion proteins comprising a polypeptide of interest and a fusion partner, wherein the junction region between the polypeptide of interest and ... 08/31/06 - 20060194292 - Growth factor complexes and modulation of cell migration and growth Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of ... 08/24/06 - 20060188964 - Processing for producing and crystallizing g-protein coupled receptors This invention provides methods for producing a membrane-bound protein in mammalian cells. This invention also provides nucleic acids for making novel fusion proteins (e.g., GPCR fusion proteins). This invention further provides related bacterial expression vectors; expression methods; fusion proteins; bacterial cells; GPCR vector screens; bacterial spheroplasts; methods for making anti-GPCR ... 08/24/06 - 20060188963 - Collectin-complement activating protein chimeras The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said ... 07/27/06 - 20060166329 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 05/18/06 - 20060105429 - Fusion polypeptides of human serum albumin and a therapeutically active polypeptide Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides. ... 05/11/06 - 20060099689 - Use of caspase enzymes for maturation of engineered recombinant polypeptide fusions The invention relates to methods of producing and isolating recombinant proteins using fusion protein constructs comprising specific recognition sites for a maturating protease. The invention specifically relates to the use of caspase proteases for the maturation of engineered recombinant fusion proteins or polypeptides. These molecules are engineered using recombinant DNA ... 04/13/06 - 20060078970 - Fusion polypeptide suitable as a cytotoxin The present invention relates to fusion polypeptides including (a) a binding site for a cytoskeleton component and (b1) an effector protein or the catalytic domain thereof or (b2) a binding site for the effector protein, and nucleic acid sequences encoding the fusion polypeptides. Moreover, various therapeutic uses of the fusion ... 04/13/06 - 20060078969 - Regulated transcription of targeted genes and other biological events Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, ... 03/23/06 - 20060063236 - Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same Chimeric polypeptide antagonists that include an interleukin-4 (IL-4) mutein linked to an interleukin-9 (IL-9) mutein are provided, as are polynucleotides encoding the IL-4 and IL-9 chimeric mutein antagonists. Also provided are methods of using the chimeric mutein antagonists and encoding polypeptides to reduce or inhibit the responsiveness of a cell ... 03/23/06 - 20060063235 - Dna encoding the human serine protease c-e Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease C-E. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease ... 03/16/06 - 20060057679 - Rage protein derivatives The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids ... 03/16/06 - 20060057678 - Chimeric proteins for diagnosis and treatment of diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of ... 03/09/06 - 20060051844 - Human epo mimetic hinge core mimetibodies, compositions, methods and uses The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, ... 03/02/06 - 20060046285 - Enhanced expression of fusion polypeptides with a biotinylation tag The invention provides the means to enhance in E. coli-based expression systems the formation of fusion polypeptides containing as an N-terminal tag a biotinylation polypeptide. By way of specifically exchanging in the nucleic acid sequence encoding the biotinylation polypeptide nucleotides at 11 discrete positions enhances the formation of the total ... 02/09/06 - 20060030008 - Modified chitin binding domain and uses thereof Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the ... 02/09/06 - 20060030007 - Peptides for metal ion affinity chromatography The invention relates generally to affinity peptides having binding activity for metal ion affinity chromatography media. The invention further relates to vectors which encode these affinity peptides and use of these affinity peptides for the purification of biological molecules such as proteins. The invention also relates to fusion proteins comprising ... 02/02/06 - 20060024794 - Novel methods for production of di-chain botulinum toxin The present invention relates to methods of manufacturing a di-chain botulinum toxin, wherein the methods do not involve the process of producing a single chain botulinum toxin that is followed by nicking to form a di-chain botulinum toxin. ... 01/19/06 - 20060014254 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 01/12/06 - 20060008883 - Methods of generating variant proteins with increased host string content and compositions thereof The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. ... 12/01/05 - 20050266533 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 12/01/05 - 20050266532 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 11/24/05 - 20050260716 - Dimeric fusion proteins and materials and methods for producing them Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a ... 11/24/05 - 20050260715 - Efficient methods for producing antimicrobial cationic peptides in host cells Endogenously produced cationic antimicrobial peptides are ubiquitous components of host defenses in mammals, birds, amphibia, insects, and plants. Cationic peptides are also effective when administered as therapeutic agents. A practical drawback in cationic peptide therapy, however, is the cost of producing the agents. The methods described herein provide a means ... 11/17/05 - 20050255561 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human ... 11/03/05 - 20050244931 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 10/27/05 - 20050239172 - Methods and dna constructs for high yield production of polypeptides The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell. ... 10/06/05 - 20050221445 - Virus coat protein/receptor chimeras and methods of use The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents ... 10/06/05 - 20050221444 - Methods and dna constructs for high yield production of polypeptides The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell. ... 09/29/05 - 20050214910 - Chordin-like molecules and uses thereof The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions ... 09/15/05 - 20050202539 - System for screening eukaryotic membrane proteins The present invention provides methods and compositions for expressing eukaryotic membrane proteins. ... 09/15/05 - 20050202538 - Fc-erythropoietin fusion protein with improved pharmacokinetics The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided. ... 09/15/05 - 20050202537 - Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins Methods and compositions for producing secreted soluble receptors and biologically active polypeptides in trimeric forms are disclosed. The process involves fusing the DNA template encoding a soluble receptor with a ligand binding domain or biologically active polypeptide to a DNA sequence encoding a C-propeptide of collagen, which is capable of ... 09/01/05 - 20050191730 - Il-4/il-13 specific polypeptides and therapeutic uses thereof Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases. ... 09/01/05 - 20050191729 - Methods for the recombinant production of antifusogenic peptides A process for the recombinant production of an antifusogenic peptide by expression of a nucleic acid encoding the antifusogenic peptide as a repeat peptide in a microbial host cell to form inclusion bodies which comprise said repeat peptide, comprising the steps of washing the inclusion bodies with a denaturing agent ... 08/25/05 - 20050186665 - Expressed ligand - vascular intercellular signaling molecule The present invention provides for a modified TIE-2 ligand 2 which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. ... 08/25/05 - 20050186664 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 08/18/05 - 20050181482 - Method for the production of an erythropoietin analog-human igg fusion proteins in transgenic mammal milk Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein. ... 08/11/05 - 20050176107 - Methods of increasing lean tissue mass using ob protein compositions The present invention provides methods of creating and using OB protein compositions with an antibody constant region or portion thereof fused to an OB protein. The fusion protein is created by attaching the polyamino acids to the OB protein moiety. The fusion proteins can then be used for various therapeutic ... 08/11/05 - 20050176106 - Use of the rtx secretion system to achieve heterologous polypeptide secretion by vibrio cholerae Compositions and methods for secreting large heterologous polypeptides are described. ... 07/28/05 - 20050164351 - Expression of glycosyltransferase in aspergillus The invention includes novel fusion DNA sequences encoding fusion polypeptides which when expressed in Aspergillus result in the expression of fusion polypeptides which when secreted result in increased levels of secretion of the desired polypeptide as compared to the expression and secretion of such polypeptides from other host systems. ... 07/21/05 - 20050158833 - Rapidly degrading gfp-fusion proteins and methods of use Green fluorescent protein (GFP) is widely used as a reporter in determining gene expression and protein localization. The present invention provides fusion proteins with a half life of ten hours or less with several embodiments having half lives of 4 hours or less. Such proteins may be constructed by fusing ... 07/21/05 - 20050158832 - Erythropoietin analog-human serum albumin fusion Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein. ... 06/30/05 - 20050142642 - Fc fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature ... 06/16/05 - 20050130269 - Fusion proteins The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems. The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In ... 06/09/05 - 20050124045 - Fc fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature ... ### FreshPatents.com Support |